SecBot SecBot
PRESS-RELEASE ·Filed Mar 3, 2026

SANA

Sana Biotechnology, Inc
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

Investors should monitor upcoming IND filings for SC451 and first-in-human data from SG293 trials as key catalysts; the extended cash runway into late 2026 reduces near-term dilution risk despite no revenue

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.82
T+0 close · Mar 3, 2026 · via day close
Latest settled
−18.06%
T+60 · $3.13
Vs SPY
−28.15%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 4 $3.82entry
  2. T+1 · 9mo ago −10.73%α −10.16% · $3.41
  3. T+5 · 8mo ago −17.54%α −16.21% · $3.15
  4. T+20 · 8mo ago −20.16%α −15.74% · $3.05
  5. T+60 · 6mo ago −18.06%α −28.15% · $3.13
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Sana Biotechnology reported Q4 and full-year 2025 financial results alongside significant clinical and operational progress, including 12-month data from its UP421 type 1 diabetes study showing survival and function of hypoimmune-modified islet cells without immunosuppression, publication in NEJM, advancement of SC451 and SG293 programs toward clinical trials, and a strengthened cash position of $138.4 million providing runway into late 2026 following $133.7 million in equity raises.

Key Financial Metrics

Adj. EPS
$-0.67
GAAP: $-0.96

Key Facts

  • 12-month clinical data from UP421 study show hypoimmune-modified islet cells survive, function, and evade immune detection without immunosuppression in a type 1 diabetes patient
  • NEJM published 12-week results and an accompanying editorial, validating scientific significance
  • SC451 (iPSC-derived hypoimmune islet therapy) on track for IND filing and Phase 1 start as early as 2026
  • SG293 (in vivo CAR-T fusosome) expected to generate first-in-human data in blood cancers in 2026
  • Raised $133.7 million via ATM and public offering in 2025; cash position at $138.4 million as of Dec 31, 2025
  • Non-GAAP net loss improved to $170.1 million in 2025 from $263.1 million in 2024 due to R&D prioritization and cost reductions
  • Appointed new CFO, Brian Piper, in Q1 2026

Financial Impact

Reduced cash burn from $195.1M in 2024 to $138.5M in 2025 (Non-GAAP); $133.7M raised in equity financing offsets operating losses

cash runwayR&D expenseoperating cash burnnet loss

Risk Factors

  • Clinical development risks in early-stage programs (SC451, SG293)
  • Heavy reliance on successful translation of preclinical/early clinical data into later-stage efficacy
  • Future financing needs beyond late 2026 could lead to dilution

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3248908

Track record

12 reports on SANA

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +13.50% at T+20 after the May 11, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $2.37 Now $1.88 −20.68% settles Dec 7
  2. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $2.34 Now $1.88 −19.66% settles Dec 4
  3. Aug 10, 202614w ago 8-K Neutral 5/10 No price data
  4. Aug 10, 202614w ago Press Release Neutral 4/10 Entry $3.79 to $3.17 Now $1.88 −50.40% ▼ −16.36% −15.30% vs SPY
  5. May 11, 202627w ago 8-K Neutral 4/10 No price data
  6. May 11, 202627w ago Press Release Bearish 6/10 Entry $3.26 to $2.82 Now $1.88 +42.33% ▲ +13.50% +11.77% vs SPY
  7. Apr 24, 202629w ago DEFA14A Neutral 4/10 Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
  8. Apr 24, 202629w ago 8-K Neutral 2/10 Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
  9. Apr 13, 202631w ago 8-K Bullish 6/10 Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
  10. Apr 13, 202631w ago Press Release Bullish 7/10 Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 3, 2026